Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Insignis Therapeutics Receives FDA Feedback for Needle-Free Treatment
Details : IN-001 is a sublingual spray that utilizes an FDA-approved epinephrine prodrug, allowing for rapid administration without needles. It is being evaluated for the treatment of anaphylaxis.
Brand Name : IN-001-Prodrug
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 05, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Insignis Therapeutics Announces Positive Results from IN-001 Study For Anaphylaxis
Details : IN-001 (epinephrine) is an adrenergic receptor agonist, small molecule drug candidate which is being evaluated for the treatment of anaphylaxis.
Brand Name : IN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 07, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Insignis Receives FDA Fast Track Designation For IN-001 in Anaphylaxis Treatment
Details : IN-001 is a sublingual spray that utilizes an FDA-approved epinephrine prodrug, allowing for rapid administration without needles. It is being evaluated for the treatment of anaphylaxis.
Brand Name : IN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 13, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IN-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : HLK Pharmacin
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 1 single dose study in healthy volunteers will compare IN-001 orally dissolving tablet (epinephrine prodrug) vs the current standard of care, EPIPEN (epinephrine injection).
Brand Name : IN-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2020
Lead Product(s) : IN-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : HLK Pharmacin
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?